CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
BIA 2-093drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02170649
NCT02170649Phase 1Completed
CompareCT.gov

The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093 in Healthy Male Volunteers

Bial - Portela C S.A.·interventional·Posted Jun 23, 2014·Updated May 8, 2017

In Brief

A Phase 1 clinical trial evaluating BIA 2-093 for Epilepsy. Completed, enrolled 12 participants.

Detailed Summary

The purpose of this study is to investigate the effect of food on the pharmacokinetics of a single 800 mg oral dose of BIA 2-093 in healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 23, 2014
Enrollment StartSep 1, 2001
Primary CompletionNov 1, 2001
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.0 years ago

Interventions

BIA 2-093drug